The R&D pipeline reflects our long-term commitment to driving change to defeat obesity, haemophilia, growth disorders and other serious chronic diseases
Scientific articles authored by Novo Nordisk scientists
Facts and figures specific to our Research & Development organisation
How we report our financial, social and environmental performance
What guides the way we do business
How we contribute to the Sustainable Development Goals
Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chron ... Read more
Novo Nordisk obtains exclusive worldwide licence to EpiDestiny's sickle cell dis ... Read more
FDA approves inclusion of data on cardiovascular outcomes and severe hypoglycaem ... Read more
Ozempic® approved in Japan for the treatment of type 2 diabetes ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
Status regarding Novo Nordisk's holding of its own shares (31 March 2018) ... Read more
Financial statement for the first three months of 2018,
Silent period,
Financial statement for the first six months of 2018,
Take an advanced view of the Novo Nordisk share
Click here to find further information
Link to conference call and presentation
Read about Novo Nordisk – A focused healthcare company
See relevant content for private investors
Download relevant Investor Relations material
Peter Hugreffe AnkersenHead of Investor Relations
Anders Mikkelsen Investor Relations Manager
Christina Kjær Investor Relations Manager
Chilie Thomsen Investor Relations Coordinator
Sign up to receive company announcements.
